Martin D. Madaus, Ph.D., has served as a director of Repligen since February 2023 and Chair of the Board since March 2026. Dr. Madaus joined the Board with over 25 years of industry experience, including five years as Chairman, President and CEO of Millipore Corporation, where he was integral to the company's transformation into a life science leader, and its acquisition by Merck KGaA in 2010.
He is an active board leader, currently serving as a director of Hologic, Inc. (since December 2024) and Azenta Life Sciences. Dr. Madaus previously served as Chairman for Quanterix Corporation and as a board member for Standard BioTools, Inc. He also serves on the boards of three private companies: Unchained Labs, Emulate Inc. and Syntis Bio.
Dr. Madaus is currently a senior operating executive at The Carlyle Group (since 2019). He previously served as Chairman and CEO at Ortho-Clinical Diagnostics from 2014 to 2019. His tenure with Roche Holding AG from 1996 to 2004 included his position from 2000 to 2004 as President and CEO, N.A. of Roche Diagnostics Corp. Dr. Madaus began his career as a veterinarian, before joining Boehringer Mannheim Corporation, where he held sales, marketing and product management roles from 1989 to 1996, until his move into general management coincided with the company's acquisition by Roche in 1996. He holds a D.V.M. from the University of Munich in Germany and a Ph.D. from the University of Veterinary Medicine of Hanover in Germany.
Where the filing does not disclose a value, this page states "Not disclosed" rather than estimating. Smaller filers are exempt from disclosing metric targets and achievement, and larger filers may omit forward targets for competitive reasons.